Transmedics Group Inc (NASDAQ:TMDX) has a beta value of 2.10 and has seen 0.83 million shares traded in the last trading session. The company, currently valued at $2.55B, closed the last trade at $75.93 per share which meant it lost -$2.74 on the day or -3.48% during that session. The TMDX stock price is -133.6% off its 52-week high price of $177.37 and 23.26% above the 52-week low of $58.27. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.98 million shares traded. The 3-month trading volume is 1.88 million shares.
The consensus among analysts is that Transmedics Group Inc (TMDX) is Buy stock at the moment, with a recommendation rating of 1.70. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 7 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.15.
Transmedics Group Inc (NASDAQ:TMDX) trade information
Sporting -3.48% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the TMDX stock price touched $75.93 or saw a rise of 7.82%. Year-to-date, Transmedics Group Inc shares have moved 21.78%, while the 5-day performance has seen it change 21.78%. Over the past 30 days, the shares of Transmedics Group Inc (NASDAQ:TMDX) have changed 11.24%. Short interest in the company has seen 8.64 million shares shorted with days to cover at 4.5.
Wall Street analysts have a consensus price target for the stock at $114.5, which means that the shares’ value could jump 33.69% from current levels. The projected low price target is $90.0 while the price target rests at a high of $145.0. In that case, then, we find that the current price level is -90.97% off the targeted high while a plunge would see the stock gain -18.53% from current levels.
Transmedics Group Inc (TMDX) estimates and forecasts
Figures show that Transmedics Group Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -45.19% over the past 6 months, with this year growth rate of 229.87%, compared to 14.80% for the industry. Revenue growth from the last financial year stood is estimated to be 77.76%.
8 analysts offering their estimates for the company have set an average revenue estimate of 109.49M for the current quarter. 6 have an estimated revenue figure of 119.4M for the next ending quarter. Year-ago sales stood 81.17M and 96.85M respectively for this quarter and the next, and analysts expect sales will grow by 34.89% for the current quarter and 77.76% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 8.36% over the past 5 years.
TMDX Dividends
Transmedics Group Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Transmedics Group Inc (NASDAQ:TMDX)’s Major holders
Insiders own 3.21% of the company shares, while shares held by institutions stand at 113.48% with a share float percentage of 117.25%. Investors are also buoyed by the number of investors in a company, with Transmedics Group Inc having a total of 502.0 institutions that hold shares in the company. The top two institutional holders are FMR LLC with over 4.49 million shares worth more than $676.31 million. As of 2024-06-30, FMR LLC held 13.7063% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 2.65 million shares as of 2024-06-30. The firm’s total holdings are worth over $398.47 million and represent 8.0755% of shares outstanding.
